Editorial Comment to “Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma”

Documenti analoghi

• Editorial Comment to “Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First‐Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real‐World Study ( YUSHIMA Study)”
  di: Nozomi Hayakawa, et al.
  Pubblicazione: (2026)
• Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma
  di: Satoshi Inoue, et al.
  Pubblicazione: (2025)
• Editorial Comment From Dr. Miyake to Effects of Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma
  di: Makito Miyake
  Pubblicazione: (2025)
• Editorial Comment to “Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real‐World Multicenter Study”
  di: Nozomi Hayakawa, et al.
  Pubblicazione: (2025)
• Editorial Comment to “Impact of Early Detection and Varying Duration of Chemoprophylaxis on Venous Thromboembolism After Robot‐Assisted Radical Cystectomy”
  di: Eiji Kikuchi, et al.
  Pubblicazione: (2025)